CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase II from Phase Ib

CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.